.Given the correlation between PD and glucose metabolism disorders and energy conversion disorders, researchers have increasingly focused on the neuroprotective effects of GLP-1.GLP-1 receptor agonists provide neuroprotection through multiple pathways, including improving insulin sensitivity, reducing oxidative stress, and enhancing mitochondrial function, as shown in Figure 2. This evidence concerns the gene GLP1R and Parkinson disease.